Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab

Overview of attention for article published in Clinical Gastroenterology and Hepatology, October 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 43 X users
facebook: 1 Facebook page

reddit: 1 Redditor
guideline: 3 clinical guideline sources

Readers on

mendeley: 32 Mendeley

So far, Altmetric has seen 48 X posts from 43 X users, with an upper bound of 142,088 followers.

RT @AGA_CGH: The October's Editors Essential Reading finds combination therapy with immunomodulators improves the pharmacokinetics of infli…

Wisam, and there I am thinking I had a reasonable vocabulary….

Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab - Clinical Gastroenterology and Hepatology. ⁦@ibdnurse⁩ https://t.co/yLtfKOmY8g

Are your IBD Teams still using IMMs in combination with Vedo or UST? You may wish to read this paper to inform future MDT decisions. 👇👇

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 44 additional X posts.